Prediction resource could make CRISPR-Cas9 editing more reliable
The largest study of CRISPR action to date has developed a method to predict the exact mutations CRISPR-Cas9 gene editing can introduce to a cell. Researchers at the Wellcome Sanger Institute edited 40,000 different pieces of DNA and analysed a thousand million resulting DNA sequences to reveal the effects of the gene editing and develop a machine learning predictive tool of the outcomes. This will assist researchers who are using CRISPR-Cas9 to research disease mechanisms and drug targets.
Reported today in Nature Biotechnology (27th November), the new resource will enable scientists to predict the best sequences to target to make CRISPR-Cas9 gene editing more reliable, and therefore cheaper and more efficient.
CRISPR-Cas9* is a gene editing technology that enables researchers to cut DNA at any position in the genome, to create mutations and switch off specific genes. This vital technology is used by scientists worldwide to study which genes are important for various conditions, from cancer to rare diseases. It is also now being trialled therapeutically to correct harmful mutations in people’s genes.
A specific guide RNA binds to an exact sequence of target DNA, guiding the Cas9 ‘scissors’ to cut the DNA at the right place. However, it is difficult to predict exactly what the final mutations will be, as further changes often take place when the cell repairs the break, rejoining the two cut ends of the DNA.
To study this, the researchers created over 40,000 pairs of different target DNA and guide RNA, and carried out CRISPR-Cas9 gene editing. By deep sequencing of each pair in different cells, they were able to analyse in detail how the DNA was cut and rejoined. They found that the repair depended on the exact sequence of DNA and guide and discovered that it was reproducible within the same sequence.
The researchers then used the huge quantity of sequence data to create a machine learning computational tool, which created general rules to determine the outcome of the repair. This programme – called FORECasT – enabled them to predict the repaired sequence, using the targeted DNA sequence alone.
“We have carried out the largest, most comprehensive study on CRISPR-Cas9 action to date, and analysed more than a thousand million DNA sequences to allow us to study the process. We demonstrated that specific target sequences were repaired by the cell in the same way, proving that the action of the cell mechanisms is reproducible.”
Dr Luca Crepaldi, joint first author on the study from the Wellcome Sanger Institute
“The discovery of reproducible DNA repair after CRISPR-Cas9 editing, combined with the vast amount of sequence data we generated, meant that we could create a predictive tool using machine learning methods. Our resource can predict the exact mutations resulting from CRISPR-Cas9 gene editing, just from the sequence of the target DNA. It will save time and resources for future CRISPR-Cas9 applications, and is openly available for use by all researchers using gene editing to study health and disease.”
Dr Felicity Allen, joint first author from the Wellcome Sanger Institute
“CRISPR-Cas9 is an extremely important system for introducing mutations into DNA for research, and prospective therapeutic purposes. Our research allows scientists to understand its workings much better, and our transformational method enables people to predict the effects of each CRISPR-Cas9 edit in a cell. This allows better design of editing experiments, and may lead to future therapeutic applications.”
Dr Leopold Parts, senior author on the paper from the Wellcome Sanger Institute
The Latest on: Gene editing
via Google News
The Latest on: Gene editing
- Gene Editing Service Market Analysis, Segments, Growth and Value Chain 2021 - 2026 | Impact of COVID-19 Pandemicon June 24, 2020 at 9:01 am
Kenneth Research has published a detailed report on Gene Editing Service Market which has been categorized by market ...
- First Patient To Receive Gene Editing Treatment For Sickle Cell Doing Well In 2020on June 23, 2020 at 5:10 pm
The first patient to receive a special gene editing treatment for sickle celldisease is surviving ― and even thriving ― a year later.Victoria Gray, 34, whose story has been chronicled by NPR for the ...
- Light-activated 'CRISPR' enables fast, precise gene editing and detection of DNA repairon June 23, 2020 at 1:05 pm
In a series of experiments co-funded by the National Science Foundation, scientists at Johns Hopkins have used light as a trigger to make quick, precise cuts in the genomic material of human cancer ...
- AAV Gene Therapy Pioneer Jude Samulski Develops Proprietary Regulated Gene Editing Systemon June 23, 2020 at 6:48 am
Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that Jude Samulski, PhD, President, Chief Scientific Officer ...
- A Year In, 1st Patient To Get Gene-Editing For Sickle Cell...on June 23, 2020 at 2:58 am
She's the first person with a genetic disorder to get treated in the United States with the revolutionary gene-editing technique called CRISPR. And as the one-year anniversary of her landmark ...
- News Brief: Trump Trip To Arizona, Primary Elections, Gene-Editing Patienton June 23, 2020 at 2:04 am
President Trump travels to Arizona to talk about his southern border wall. Five states hold primary elections. And, an update on the first U.S. patient to get treatment from a gene-editing technique.
- A Year In, 1st Patient To Get Gene Editing For Sickle Cell Disease Is Thrivingon June 23, 2020 at 2:04 am
Since receiving a landmark treatment with the gene-editing tool CRISPR, a sickle cell patient has the strength to care for herself and her children — while navigating the pandemic.
- A promise to a friendon June 5, 2020 at 2:40 pm
Technologies like hearing aids and cochlear implants can amplify sound but can’t correct the problem. Perhaps gene editing could, scientists decided, since genetic anomalies contribute to half of all ...
- Gene-edited T cells to treat diabetes inch closer to clinical trialson June 3, 2020 at 11:05 am
Scientists from the Seattle Children’s Research Institute and the Benaroya Research Institute have found a potential way to turn off the destructive autoimmune response in Type 1 diabetes—and ...
via Bing News